Selected engagements with the numbers up front. Cases are anonymized; the work and the results are real.
A clinical-stage biotech’s first launch: commercial strategy choices, distilled to the sixteen that decide launch success, sequenced from board to team.
Read the case →A top 20 global biopharma, a five-year portfolio plan, and an outcome 36 percent above pre-launch consensus.
Read the case →Confident facing the competition, before and after the simulation: a top-40 global pharma’s leadership, stress-tested across two full-scale launch simulations.
Read the case →If your organization is launching a new therapy where failure is not an option, let’s talk.
Start a conversation